Critical Care Self-Assessment Program (CCSAP) (Cert #L259047)
ACPE Numbers: Various – see listing below Release Date: March 17, 2025 Expiration Dates: March 17, 2026 Activity Type: Application-based CE Credits: 23.5 contact hours (BPS and ACPE) Activity Fee: $88 (ASHP member); $132 (non-member)
Activity Overview
This course is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by Board of Pharmacy Specialties (BPS). The course consists of 10 learning modules (see table below) and provides up to 23.5 contact hours of continuing pharmacy education and/or recertification credit.
Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.
These activities are part of the ACCP and ASHP professional development program for BCCCP recertification approved by the BPS.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.
Board certified pharmacists are eligible to receive up to 23.5 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.
ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.
ACCP and ASHP are approved by BPS as a provider for the recertification of BCCCP .
Learning Activity
Passing Score
Credit Information
Management of HIV and HCV Infection
73%
4.0 Contact Hours
BPS: BCCCP ACPE: 0217-9999-25-030-H01-P
Heart Failure in the ICU
80%
2.5Contact Hours
BPS: BCCCP ACPE: 0217-9999-25-031-H01-P
Case Series: Rapid Sequence Intubation
75%
2.5 Contact Hours
BPS: BCCCP ACPE: 0217-9999-25-032-H01-P
Hepatorenal Syndrome
80%
1.5 Contact Hours
BPS: BCCCP ACPE: 0217-9999-25-033-H01-P
Burn Management
73%
2.0 Contact Hours
BPS: BCCCP ACPE: 0217-9999-25-034-H01-P
Case Series: Spinal Cord Injury
83%
2.0 Contact Hours
BPS: BCCCP ACPE: 0217-9999-25-035-H01-P
Management of Solid Organ Transplant Patients
73%
2.0 Contact Hours
BPS: BCCCP ACPE: 0217-9999-25-036-H01-P
Postoperative Care of the Surgical Patient
80%
2.5 Contact Hours
BPS: BCCCP ACPE: 0217-9999-25-037-H01-P
Case Series: Pharmacoeconomic Evaluation of Critical Care Therapies
Management of HIV and HCV Infection ACPE #: 0217-9999-25-030-H01-P
Evaluate appropriate antiretroviral therapy in patients admitted to the ICU.
Compare and contrast factors that may influence antiretroviral therapy in a critically ill patient.
Identify appropriate hepatitis C therapy in patients admitted to the ICU.
Develop a plan for the management of hepatitis C virus in critically ill patients.
Heart Failure in the ICU ACPE #: 0217-9999-25-031-H01-P
Distinguish differences among hemodynamic profiles used to tailor pharmacotherapies.
Develop patient-specific treatment goals on the basis of identification of cardiogenic shock stage.
Delineate the place in therapy of both decongestive and vasoactive therapies for the treatment of acute heart failure (AHF).
Assess the clinical appropriateness of de-escalating AHF therapies as filling pressure and decongestion targets are achieved.
Case Series: Rapid Sequence Intubation ACPE #: 0217-9999-25-032-H01-P
Assess and analyze components of the rapid sequence intubation (RSI) procedure in critically ill patients and evaluate the current standards of practice.
Design a safe and effective medication treatment regimen taking into account patient-specific risk factors in critically ill patients undergoing RSI.
Distinguish clinical scenarios in which a modified approach to RSI may be warranted depending on specific clinical considerations.
Design practices to optimize patient health outcomes related to RSI in critically ill patients.
Evaluate and assess for current evidence gaps and areas for future research as it pertains to pharmacist-related optimization of current RSI practices.
Evaluate risk factors for developing hepatorenal syndrome (HRS).
Analyze patient characteristics to determine the presence of HRS.
Assess the clinical appropriateness of treatments for HRS.
Compare and contrast risk-benefit of treatments for HRS.
Identify appropriate monitoring values for treatments for HRS.
Burn Management ACPE #: 0217-9999-25-034-H01-P
Classify burns according to depth and size of injury.
Devise a fluid resuscitation plan for the patient with severe burn injury.
Develop a pharmacotherapy-centric treatment plan for the patient with acute inhalation injury.
Design a patient-centered analgesia plan after acute burn injury.
Design a treatment plan for the patient who develops sepsis after acute burn injury.
Case Series: Spinal Cord Injury ACPE #: 0217-9999-25-035-H01-P
Evaluate patients for injury patterns and clinical manifestations of acute spinal cord injury.
Develop appropriate therapeutic plans for the hemodynamic management of acute spinal cord injuries.
Distinguish effective and safe intravenous vasoactive agent(s) for achieving individual mean arterial pressure targets based on current literature and individual patient characteristics.
Evaluate the utility of enteral vasoactive agents for ongoing neurogenic shock.
Develop appropriate supportive care plans for the patient with acute spinal cord injury.
Management of Solid Organ Transplant Patients ACPE #: 0217-9999-25-036-H01-P
Design appropriate immunosuppression modifications on the basis of risk factors and time after transplantation in patients admitted to the ICU.
Compare and contrast factors that may influence the approach to critically ill solid organ transplant (SOT) recipients on the basis of type of transplantation.
Design management for common scenarios specific to critically ill SOT recipients.
Develop a plan for managing common scenarios specific to critically ill SOT recipients.
Postoperative Care of the Surgical Patient ACPE #: 0217-9999-25-037-H01-P
Justify critical care pharmacist involvement in post-surgical care and its impact on patient outcomes.
Design evidence-based protocols for immediate postoperative care including pain management and venous thromboembolism prevention.
Assess which patient populations should receive postoperative antibiotics, which agent(s) should be used, and an appropriate duration of therapy.
Design optimal pharmacotherapy for common postoperative complications, taking patient-specific factors into consideration.
Case Series: Pharmacoeconomic Evaluation of Critical Care Therapies ACPE #:0217-9999-25-038-H01-P
Distinguish between different types of economic studies that are part of pharmacoeconomic studies.
Evaluate the pharmacoeconomic evidence available in highlighted disease states.
Design strategies to understand financial impacts of the medication use process, including medication shortages.
Best Practices in Disease-Specific Core Measures ACPE #: 0217-9999-25-039-H01-P
Assess the importance of core measures within the critical care landscape.
Analyze the role of major regulatory bodies in setting core measures and discuss how these measures influence patient care and hospital accreditation.
Evaluate core measures updates and best practices in managing critical care conditions.
Develop strategies for implementing and monitoring core measures in critical care settings.
Distinguish future trends in critical care quality core measures.
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ACCP and ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
The following persons in control of this activity’s content have relevant financial relationships:
Consultancies: Brooke Barlow (Grifols); Molly Droege (SaNOtize Research and Development); Gabriel V. Fontaine (AstraZeneca, Chiesi, Marinus Pharmaceuticals, Anticoagulation Forum); Tudy Hodgman (ACCP); Desiree Kosmisky (Carolinas/Virginias Chapter of the Society of Critical Care Medicine); Rachel Kruer (Wolters Kluwer); Brittany Bissell Turpin (Lexicomp); Patrick M. Wieruszewski (La Jolla Pharmaceutical Company)
Grants: Nicole M. Acquisto (Melinta Therapeutics); Tyree (Ty) Heath Kiser (Allergan); Andrea Sikora (AHRQ); Zachary R. Smith (Shields Health Solutions)
Honoraria: Molly Droege (ACCP) (two honoraria) Gabriel V. Fontaine (AstraZeneca, Chiesi, Anticoagulation Forum); Paul M. Reynolds (Prime Medical Education)
Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:
Complete the attestation statement
Review all content
Complete and pass the assessments
Complete the evaluations
Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.
